Immunogen (IMGN) Announces In-Line Q3 EPS, Reports $245.8M of Cash and Cash Equivalents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- US considers new sanctions on Brazilian judge, FT reports
- Six dead in 'stampede-like' incident at India temple, ANI says
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
October 29, 2021 6:30 AM EDTTop-Line Data from Pivotal SORAYA Trial Evaluating Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer on Track for Release this Quarter
IMGN632 AML Combination Data to be Highlighted at ASH Annual Meeting
PICCOLO, Single-Arm Study of Mirvetuximab in Platinum-Sensitive Ovarian Cancer, Open for Enrollment
Earlier-Stage Pipeline Continues to Progress
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS... More
